
Wildfires send Canada's carbon emissions soaring. And our peatlands emit even more
It's been another smoky summer, with estimates suggesting that 2025 is set to be Canada's second-worst wildfire season year. Already, more than 5.5 million hectares have burned, almost triple the 10-year average for this time of the year.
But it's not just the forests that are burning. Canada is home to a quarter of the world's peatlands — boggy wetlands that are a rich store of carbon from millions of years of decaying plant and animal life.
They are burning, too. But the scale of emissions from fires in the peatlands is not accounted for in current government statistics.
However, that's all about to change, with a new government effort to estimate peatland emissions and their impact on climate change.
"The better able I am to quantify these impacts, the better able we might be able to mitigate them," said Kelly Bona, who is leading the effort to produce a Canadian model for peatland emissions at Environment and Climate Change Canada.
Bona said the new data could be included as early as next year in Canada's official greenhouse gas reporting to the UN. Its inclusion would provide a new look at the severity of the problem, which researchers say is getting worse.
Why peatland fires are a climate problem
Much of Canada's peatlands are in the boreal forest zone, where trees like black spruce — which are prone to burning — are common. The presence of those trees, along with rich carbon deposits in the soil, can make peatlands very flammable, especially during dry periods.
Peat fires also smoulder over longer periods, rather than going up in one giant flame. Some of these fires can burn for months or years, according to researchers, releasing large amounts of their stored carbon into the atmosphere.
Greg Verkaik, a peatlands researcher and PhD candidate at McMaster University, collects post-fire field measurements to estimate the emissions. He painstakingly measures the depth of the peat at various points to figure out how much has been burned.
His time in the field provides him with a close look at the impact of climate change and worsening wildfires.
"You get days where you just can't go into the field because everything's smoky and it's hard to breathe and it's not safe for you to be out there," he said.
"You are sort of seeing that more frequently, especially over these last couple of fire seasons where it's been really bad."
Wildfire emissions don't count toward Canada's anthropogenic (human-caused) totals, but they are still reported to help inform the public and keep track of how forests are doing.
In recent years, the statistics have been sobering — wildfire emissions in 2023, the worst fire year in Canada's history, reached one billion tonnes — significantly more than the 694 million tonnes of emissions attributed to human activity.
The feedback loop is that climate change has made fire weather more frequent and severe, and those fires are worsening climate change itself.
In the peatlands, research has shown wildfires speed up permafrost melt, which in turn releases carbon, according to David Olefeldt, a peatlands researcher and assistant professor at the University of Alberta.
Olefeldt also said that peatlands continue emitting carbon long after a fire, as all the carbon in the soil takes longer to be lost to the atmosphere.
"If you want to understand the full impact of wildfire, you need to understand what happens in the years and even the decades after the fire," he said.
A study published in 2024 used the Canadian-developed model to estimate greenhouse gas emissions from Canada's boreal and temperate peatlands. Preliminary results suggest that fire-related emissions are about 11.5 million tonnes annually but noted estimates can vary significantly from one year to the next.
Wildfires over the past few years highlight those variations. 2020 was a mild fire year, with emissions of only 13 million tonnes, while 2021 was a more severe season, with emissions skyrocketing to 270 million tonnes.
According to the study, peatlands are generally a carbon sink, absorbing and storing more carbon than they emit, therefore helping counteract the effects of climate change.
But during a severe fire season, they become a carbon source, and release more than they absorb.
How could better peatland emissions numbers be used?
The new data would have a range of practical uses, both for resource development as well as conservation in the peatlands.
Bona said the data could be used in conducting environmental assessments for peatland projects. Olefeldt noted that knowing more about peatland emissions — including identifying ones those that are most at risk — could help aid in discussions about protecting them.
Maria Strack, a professor at the University of Waterloo who leads Can-Peat, a major research collaboration on the peatlands, pointed out that most peatlands are in regions where there's an interest in resource extraction.
The new data could help inform future decisions on developing mines and other infrastructure in those areas, she said.
"There's risks of mining disturbing more peat and all the infrastructure like roads to access those mines will also change the hydrology of peatlands, which could lead to more emissions."
She also sees them as a nature-based solution to combating climate change.
"We have about one-fourth of all the world's peat soil carbon stock, and I just think most Canadians don't even know what a peatland is," she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
2 hours ago
- National Post
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. Article content A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has served on advisory boards for industry, government, and academia, and served as CTO for Teloquent (acquired by Syntellect), Empirix (acquired by InfoVista), and BA Insight (acquired by Upland Software), as well as product leadership roles at FAST Search and Microsoft. Article content Mr. Fried has been an enthusiastic advocate for IPA's LENS ai ™ platform, praising its ability to unify biological sequence, structure, function, and scientific literature into a searchable, AI-ready framework. He has played a pivotal role in supporting BioStrand's partnership with InterSystems to integrate advanced vector search capabilities into LENS ai —helping unlock powerful new possibilities for AI-driven research, diagnostics, and therapeutic development. Article content 'We are excited to welcome Jeff to our Advisory Board at a time when our vision for a scalable, bio-native AI infrastructure is rapidly becoming a reality,' said Dr. Jennifer Bath, CEO of IPA. 'Jeff's insights at the intersection of healthcare data architecture and AI-enabled discovery are invaluable as we continue to expand LENS ai 's capabilities and reach across life sciences.' Article content 'LENS ai is one of the most exciting AI platforms I've encountered in the life sciences space,' said Fried. 'It solves a foundational problem—making biological data interoperable and computationally accessible at scale. I'm thrilled to contribute to IPA's vision and help shape the future of bio-native AI drug discovery.' Article content Fried's appointment underscores IPA's commitment to enabling discovery work at the speed of computation, not convention, by providing the bio-native AI infrastructure the life sciences industry truly needs—fast, scalable, and grounded in real biological data. Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT ® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the Company's strategic direction, the Company's future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. Article content Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in AI and biotechnology; and other risks inherent to the Company's industry and business model. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Article content Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Article content Article content Article content Article content Contacts Article content Article content Article content


CTV News
3 hours ago
- CTV News
Halifax's Hope Blooms goes solar
Atlantic Watch Crystal Garrett visits Hope Blooms in Halifax to check out their new solar tracking system.


Globe and Mail
10 hours ago
- Globe and Mail
3 Monster Stocks in the Making to Buy Right Now
Key Points CRISPR Therapeutics is still in its early growth stage. Summit Therapeutics has plenty of upside potential remaining. Viking Therapeutics is targeting two monster markets. 10 stocks we like better than CRISPR Therapeutics › Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings. Three Motley Fool contributors think they've identified monster stocks in the making. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX). Image source: Getty Images. A promising company in its early growth stage David Jagielski (CRISPR Therapeutics): Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable in the long run. The gene editing market is still fairly small, but it has a lot of room to grow. Analysts from Grand View Research project that it will expand at a compound annual growth rate of more than 16% between now and 2030, when it will be worth $25 billion. As a leading company in the space, CRISPR Therapeutics is well positioned to benefit from future growth in this area of healthcare. The company, and its key development partner, Vertex Pharmaceuticals (NASDAQ: VRTX), already have an approved gene therapy treatment in Casgevy, which regulators have approved for both sickle cell disease and transfusion-dependent beta-thalassemia. The companies will share in the profits on the treatment (CRISPR will take 40%). Casgevy is still in its early growth stages. CRISPR is also working on developing treatments for type 1 diabetes and cardiovascular disease. While CRISPR remains unprofitable today, its future does look bright. It's a long road ahead for CRISPR Therapeutics, but with an encouraging pipeline and a lot of growth potential, this could be a monster healthcare stock in the making. The business is well funded with its cash and marketable securities as of the end of March totaling nearly $1.9 billion, putting it in an excellent position to continue investing in its research and development efforts. CRISPR can make for an excellent investment, but it's also one you'll need to be patient with. Still plenty of upside left for this stock Prosper Junior Bakiny (Summit Therapeutics): Few biotech companies have performed better than Summit Therapeutics over the past three years. The company's shares have soared by more than 2,000%, making early investors who held on significantly wealthier in the process. Here's the good news for those who are still considering the stock: There could be a massive upside left for Summit Therapeutics. Though the biotech generates no revenue and is unprofitable, it has one of the more promising pipeline products in the industry. Summit Therapeutics' leading candidate is a cancer medicine called ivonescimab, which it licensed out from Akeso Biopharma (OTC: AKES.F), a China-based drug developer. The medicine has been extensively tested in China, where it has already received approval in certain indications. One of ivonescimab's most promising markets is non-small cell lung cancer (NSCLC). In a phase 3 study in China, it went head-to-head against the market leader and the world's best-selling drug: Merck 's (NYSE: MRK) Keytruda. Ivonescimab emerged victorious, leading to a greater decrease in the risk of recurrence or death among NSCLC patients with a PD-L1 protein overexpression. Summit Therapeutics is conducting clinical studies to support approval in the U.S. and other regions. Furthermore, the biotech is likely to seek a series of approvals and label expansions over the years, based on the number of clinical trials and indications Akeso is targeting in China. Ivonescimab should easily become a blockbuster and generate strong sales for years. That's why it's not too late to invest in Summit Therapeutics. If ivonescimab achieves its full potential, Summit could deliver market-beating returns in the next five to 10 years and establish itself as a prominent player in the biotech industry. Targeting two monster markets Keith Speights (Viking Therapeutics): The big story for Viking Therapeutics is its experimental obesity drug VK2735. The company recently advanced a subcutaneous formulation of this candidate into late-stage clinical testing after announcing highly encouraging results from a phase 2 study last year. Viking is also evaluating an oral version of VK2735 in a separate phase 2 clinical trial, and it expects to report results from that study later in 2025. In addition, the drugmaker plans to initiate a clinical study for a monthly maintenance version of subcutaneous VK2735 in the coming months. Morgan Stanley Research projects that the global obesity drug market could reach $150 billion by 2035. Viking could be in a great position to claim a nice chunk of that market if VK2735 fulfills its potential. Obesity isn't the only big market that the company is targeting, though. In 2023, Viking reported positive results from a phase 2 study of VK2809 in treating metabolic-associated steatohepatitis (MASH), a chronic liver disease also known as nonalcoholic steatohepatitis (NASH). The company is seeking a partner to advance VK2809 into late-stage testing, so it can dedicate its financial resources exclusively to VK2735 for now. Grand View Research predicts the MASH/NASH market could hit $33.8 billion by 2030, so that's a nice opportunity. A clinical trial flop for VK2735 and/or a failure to find a partner for VK2809 could prevent Viking from becoming a monster stock. However, I think the company's chances look pretty good. I also wouldn't be surprised if a larger drugmaker swoops in to acquire Viking. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025